205 related articles for article (PubMed ID: 2319513)
1. In vitro anaerobic data on ticarcillin/clavulanate. A review of an ongoing survey.
Sanders CV; Aldridge KE
J Reprod Med; 1990 Mar; 35(3 Suppl):313-6. PubMed ID: 2319513
[TBL] [Abstract][Full Text] [Related]
2. Implications of beta-lactamase-inhibitor combinations.
Fuchs PC; Barry AL
J Reprod Med; 1990 Mar; 35(3 Suppl):317-21. PubMed ID: 2319514
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
4. Ampicillin-sulbactam and ticarcillin-clavulanic acid: a comparison of their in vitro activity and review of their clinical efficacy.
Itokazu GS; Danziger LH
Pharmacotherapy; 1991; 11(5):382-414. PubMed ID: 1745624
[TBL] [Abstract][Full Text] [Related]
5. [Comparative bacteriostatic activity of ticarcillin, alone and combined with clavulanic acid, 5 cephalosporins and metronidazole against 100 strains of Bacteroides fragilis].
de Barbeyrac B; Quentin C; Bebear C
Pathol Biol (Paris); 1984 May; 32(5):433-5. PubMed ID: 6739151
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units.
Gill CJ; Ponticas S; Shungu DL; Guerriero S
Clin Ther; 1991; 13(1):25-37. PubMed ID: 2029725
[TBL] [Abstract][Full Text] [Related]
7. Development of beta-lactamase inhibitors.
Sutherland R
J Reprod Med; 1990 Mar; 35(3 Suppl):307-12. PubMed ID: 2319512
[TBL] [Abstract][Full Text] [Related]
8. Newer beta-lactam agents and the Bacteroides fragilis group.
Cuchural GJ
Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.
Downes J; Andrew JH
Pathology; 1988 Jul; 20(3):260-3. PubMed ID: 3205597
[TBL] [Abstract][Full Text] [Related]
10. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
Jacobs MR; Spangler SK; Appelbaum PC
J Antimicrob Chemother; 1990 Sep; 26(3):361-70. PubMed ID: 2228827
[TBL] [Abstract][Full Text] [Related]
11. [In vitro activity of the combination ticarcillin-clavulanic acid on bacterial isolates in surgery].
Branger C; Kitzis M; Le Mée J
Pathol Biol (Paris); 1986 Apr; 34(4):245-8. PubMed ID: 3528998
[TBL] [Abstract][Full Text] [Related]
12. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
14. Activity of ampicillin/sulbactam, ticarcillin/clavulanate, clarithromycin, and eleven other antimicrobial agents against anaerobic bacteria isolated from infections in children.
Citron DM; Goldstein EJ; Kenner MA; Burnham LB; Inderlied CB
Clin Infect Dis; 1995 Jun; 20 Suppl 2():S356-60. PubMed ID: 7548597
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group.
Bourgault AM; Lamothe F
J Antimicrob Chemother; 1986 May; 17(5):593-603. PubMed ID: 3636324
[TBL] [Abstract][Full Text] [Related]
16. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.
Barry AL; Jones RN; Packer RR
J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222
[No Abstract] [Full Text] [Related]
17. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of the activity of first and second generation cephalosporins and their combinations with beta-lactamase inhibitors against Bacteroides fragilis.
Martin MA; Liebana J; Castillo AM; Gutierrez J; Piédrola G
Microbios; 1991; 67(272-273):195-202. PubMed ID: 1779879
[TBL] [Abstract][Full Text] [Related]
19. Augmentation effect of clavulanic acid with penicillin, cephalothin and ticarcillin against Bacteroides fragilis.
Bansal MB; Chuah SK; Oryema-Lalobo M; Thadepalli H
Chemotherapy; 1985; 31(3):173-7. PubMed ID: 3996086
[TBL] [Abstract][Full Text] [Related]
20. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains.
Paniagua GL; Monroy E; García O; Vaca S
Rev Latinoam Microbiol; 1998; 40(3-4):128-34. PubMed ID: 10932741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
